181 related articles for article (PubMed ID: 19995744)
1. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
2. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Beyer C; Distler JH; Distler O
Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
4. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
Bibi Y; Gottlieb AB
J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
[TBL] [Abstract][Full Text] [Related]
5. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Distler JH; Distler O
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
[TBL] [Abstract][Full Text] [Related]
7. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
[TBL] [Abstract][Full Text] [Related]
8. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A
Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472
[TBL] [Abstract][Full Text] [Related]
9. Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
11. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
Iwamoto N; Distler JH; Distler O
Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
Akhmetshina A; Dees C; Pileckyte M; Maurer B; Axmann R; Jüngel A; Zwerina J; Gay S; Schett G; Distler O; Distler JH
FASEB J; 2008 Jul; 22(7):2214-22. PubMed ID: 18326784
[TBL] [Abstract][Full Text] [Related]
14. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
15. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel?
Wollheim FA
Arthritis Rheum; 2007 Jan; 56(1):9-12. PubMed ID: 17195185
[No Abstract] [Full Text] [Related]
17. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
18. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
19. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
Lazar J; Poonawalla T; Teng JM
Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]